CRBP Corbus Pharmaceuticals Holdings Inc.

6.75
-0.10  -1%
Previous Close 6.85
Open 6.95
Price To book 9.00
Market Cap 338988443
Shares 50,220,510
Volume 368,640
Short Ratio 13.93
Av. Daily Volume 494,359

SEC filingsSee all SEC filings

  1. 8-K - Current report 171062160
  2. 8-K - Current report 171045392
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171016578
  4. 8-K - Current report 171016435
  5. 8-K - Current report 17896056

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released March 30, 2017 - primary endpoint met but some concerns regarding efficacy.
Anabasum (Resunab)
Cystic Fibrosis
Phase 2 trial to be initiated 4Q 2017.
Anabasum (Resunab)
Systemic lupus erythematosus (SLE)
Phase 2 data due 4Q 2017.
Anabasum (Resunab)
Dermatomyositis
Phase 2 data released November 14, 2016. Phase 3 trial to be initiated 4Q 2017 with data due end of 2019.
Anabasum (Resunab)
Systemic Sclerosis

Latest News

  1. Corbus Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference
  2. Aldeyra Therapeutics (ALDX) Soars: Stock Adds 34.5% in Session
  3. ETFs with exposure to Corbus Pharmaceuticals Holdings, Inc. : September 12, 2017
  4. Is There Now An Opportunity In Corbus Pharmaceuticals Holdings Inc (CRBP)?
  5. 3 Reasons Momentum Stock Investors Will Love Corbus Pharmaceuticals Holdings (CRBP)
  6. Advanced Accelerator Applications (AAAP) in Focus: Stock Moves 7.5% Higher
  7. Surging Earnings Estimates Signal Good News for Corbus Pharmaceuticals (CRBP)
  8. ETFs with exposure to Corbus Pharmaceuticals Holdings, Inc. : August 31, 2017
  9. Corbus Pharmaceuticals to Host Fireside Chat on Dermatomyositis with Expert Physician and Researcher, Victoria Werth, MD
  10. Corbus Pharmaceuticals Holdings, Inc. :CRBP-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
  11. Corbus Pharmaceuticals Holdings, Inc. breached its 50 day moving average in a Bearish Manner : CRBP-US : August 15, 2017
  12. Today's Research Reports on Stocks to Watch: Genocea Biosciences and Corbus Pharmaceuticals
  13. Corbus Pharmaceuticals reports 2Q loss
  14. Corbus Pharmaceuticals Reports 2017 Second Quarter Financial Results and Provides Business Update
  15. Top 4 Marijuana Stocks to Watch for August 2017
  16. Corbus Pharmaceuticals to Present New Data from Systemic Sclerosis Phase 2 Study of Anabasum at the 15th International Workshop on Scleroderma Research
  17. It's High Time For The Cannabis-Related Drug Pipeline
  18. Corbus Pharmaceuticals Holdings, Inc. breached its 50 day moving average in a Bearish Manner : CRBP-US : July 25, 2017
  19. ETFs with exposure to Corbus Pharmaceuticals Holdings, Inc. : July 24, 2017
  20. Why I Will Never Invest in Marijuana Stocks

SEC Filings

  1. 8-K - Current report 171062160
  2. 8-K - Current report 171045392
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171016578
  4. 8-K - Current report 171016435
  5. 8-K - Current report 17896056
  6. 8-K - Current report 17874138
  7. 8-K - Current report 17826397
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 17824849
  9. 8-K - Current report 17824827
  10. 8-K - Current report 17768869